• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于光散射的纳米晶体溶解新方法的开发。

Development of a new method to assess nanocrystal dissolution based on light scattering.

机构信息

Research Pharmaceutics and Drug Product Development, Merck Serono, Frankfurter Str. 250, 64293, Darmstadt, Germany.

出版信息

Pharm Res. 2012 Oct;29(10):2887-901. doi: 10.1007/s11095-012-0795-4. Epub 2012 Jun 12.

DOI:10.1007/s11095-012-0795-4
PMID:22688901
Abstract

PURPOSE

Nanocrystals exhibit enhanced dissolution rates and can effectively increase the bioavailability of poorly water soluble drug substances. However, methods for in vitro characterization of dissolution are unavailable. The objective of this study was to develop an in situ noninvasive analytical method to measure dissolution of crystalline nanosuspensions based on light scattering.

METHODS

Fenofibrate nanosuspensions were prepared by wet media milling. Their solubilities and dissolution profiles in simulated gastric fluid supplemented with 0.1% Tween(®) 80 were measured in a small scale setup with an instrument for dynamic light scattering and the intensity of scattered light as readout parameter.

RESULTS

A good correlation was achieved between the dissolution profile of a nanosuspension measured in the light scattering setup and a conventional dissolution experiment. Nanosuspensions of 120-270 nm size could be distinguished by the light scattering method. The suspensions dissolved within 1.9-12.3 min. Over a concentration range of 40-87% of the solubility dissolution profiles of a nanosuspension with 140 nm were monitored and the determined total dissolution times were in good agreement with the Noyes-Whitney dissolution model.

CONCLUSIONS

A noninvasive, sensitive and reproducible method is presented to assess nanocrystal dissolution. In situ measurements based on light scattering allow a straightforward experimental setup with high temporal resolution.

摘要

目的

纳米晶体表现出增强的溶解速率,并且可以有效地提高水溶性差的药物物质的生物利用度。然而,目前缺乏用于体外溶解特性表征的方法。本研究的目的是开发一种基于光散射的用于测量结晶纳米混悬剂溶解的原位非侵入性分析方法。

方法

通过湿介质研磨制备非诺贝特纳米混悬剂。在配备动态光散射仪器的小型设备中,使用含有 0.1%吐温 80 的模拟胃液,测量其在模拟胃液中的溶解度和溶解曲线。以散射光强度作为读出参数。

结果

光散射装置中测量的纳米混悬剂的溶解曲线与常规溶解实验之间具有良好的相关性。光散射方法可区分 120-270nm 大小的纳米混悬剂。混悬剂在 1.9-12.3 分钟内溶解。在 40-87%溶解度范围内监测了粒径为 140nm 的纳米混悬剂的溶解曲线,并且确定的总溶解时间与 Noyes-Whitney 溶解模型吻合良好。

结论

本研究提出了一种用于评估纳米晶体溶解的非侵入性、灵敏且重现性好的方法。基于光散射的原位测量方法具有简单的实验设置和高时间分辨率。

相似文献

1
Development of a new method to assess nanocrystal dissolution based on light scattering.基于光散射的纳米晶体溶解新方法的开发。
Pharm Res. 2012 Oct;29(10):2887-901. doi: 10.1007/s11095-012-0795-4. Epub 2012 Jun 12.
2
Insight into the mechanism behind oral bioavailability-enhancement by nanosuspensions through combined dissolution/permeation studies.通过联合溶解/渗透研究深入了解纳米混悬剂提高口服生物利用度的机制。
Eur J Pharm Sci. 2023 May 1;184:106417. doi: 10.1016/j.ejps.2023.106417. Epub 2023 Mar 2.
3
Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.对由固体分散体辅料(Soluplus®)稳定的纳米混悬剂进行研究以提高生物利用度。
Int J Pharm. 2014 Dec 30;477(1-2):88-95. doi: 10.1016/j.ijpharm.2014.10.025. Epub 2014 Oct 14.
4
Formulating food protein-stabilized indomethacin nanosuspensions into pellets by fluid-bed coating technology: physical characterization, redispersibility, and dissolution.采用流化床包衣技术将食物蛋白稳定的吲哚美辛纳米混悬剂制成丸剂:物理特性表征、再分散性和溶出度。
Int J Nanomedicine. 2013;8:3119-28. doi: 10.2147/IJN.S46207. Epub 2013 Aug 14.
5
Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion.结晶药物纳米混悬液的干燥——表面疏水性对再分散后溶解行为的重要性。
Eur J Pharm Sci. 2008 Sep 2;35(1-2):127-35. doi: 10.1016/j.ejps.2008.06.009. Epub 2008 Jul 3.
6
Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.通过介质研磨技术提高口服生物利用度的头孢地尼纳米混悬液:制剂、表征及体内外评价
Drug Dev Ind Pharm. 2016;42(5):758-68. doi: 10.3109/03639045.2015.1104344. Epub 2015 Nov 7.
7
Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of Vitamin E TPGS and nanocrystal particle size on oral absorption.通过湿磨介质技术制备纳米混悬剂的配方和工艺参数优化:维生素 E TPGS 和纳米晶体粒径对口服吸收的影响。
Eur J Pharm Sci. 2012 Nov 20;47(4):718-28. doi: 10.1016/j.ejps.2012.08.011. Epub 2012 Aug 24.
8
Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.含有冬凌草甲素/羟丙基-β-环糊精包合物的纳米混悬剂,通过改善溶解和渗透性提高口服生物利用度。
AAPS PharmSciTech. 2016 Apr;17(2):400-8. doi: 10.1208/s12249-015-0363-4. Epub 2015 Jul 18.
9
Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals.制备并评价非诺贝特纳米晶的体内外性质。
Int J Pharm. 2013 Oct 15;455(1-2):267-75. doi: 10.1016/j.ijpharm.2013.07.021. Epub 2013 Jul 20.
10
Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.通过超声沉淀法制备无定形纳米混悬剂并利用实验设计方法进行制剂和工艺优化。
Int J Pharm. 2019 Mar 25;559:348-359. doi: 10.1016/j.ijpharm.2019.01.054. Epub 2019 Feb 2.

引用本文的文献

1
Numerical modeling of the dissolution of drug nanocrystals and its application to industrial product development.药物纳米晶体溶解的数值模拟及其在工业产品开发中的应用。
ADMET DMPK. 2022 Aug 4;10(4):253-287. doi: 10.5599/admet.1437. eCollection 2022.
2
Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors.-carfilzomib 纳米晶体的系统传递至实体瘤的尺寸优化。
J Control Release. 2022 Dec;352:637-651. doi: 10.1016/j.jconrel.2022.10.041. Epub 2022 Nov 5.
3
Nano-Dry-Melting: A Novel Technology for Manufacturing of Pharmaceutical Amorphous Solid Dispersions.

本文引用的文献

1
Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility.比较预测溶解的方法和粒径依赖性溶解度的理论意义。
J Pharm Sci. 2012 Feb;101(2):681-9. doi: 10.1002/jps.22778. Epub 2011 Oct 11.
2
Mathematical modeling of variables involved in dissolution testing.溶出度试验中相关变量的数学建模。
J Pharm Sci. 2011 Nov;100(11):4934-42. doi: 10.1002/jps.22673. Epub 2011 Jun 23.
3
Turbidity spectroscopy for characterization of submicroscopic drug carriers, such as nanoparticles and lipid vesicles: size determination.
纳米干熔法:一种制备药物无定形固体分散体的新技术。
Pharmaceutics. 2022 Oct 9;14(10):2145. doi: 10.3390/pharmaceutics14102145.
4
PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML).基于聚乙二醇 - 瓶刷稳定剂的蠕虫状纳米晶体胶束,具有长循环和控释功能,用于递送针对慢性粒细胞白血病(CML)的BCR-ABL抑制剂。
Pharmaceutics. 2022 Aug 10;14(8):1662. doi: 10.3390/pharmaceutics14081662.
5
Progress in the development of stabilization strategies for nanocrystal preparations.纳米晶体制剂稳定策略的发展进展。
Drug Deliv. 2021 Dec;28(1):19-36. doi: 10.1080/10717544.2020.1856224.
6
Development of new in vitro models of lung protease activity for investigating stability of inhaled biological therapies and drug delivery systems.开发新型体外肺蛋白酶活性模型,以研究吸入性生物疗法和药物输送系统的稳定性。
Eur J Pharm Biopharm. 2020 Jan;146:64-72. doi: 10.1016/j.ejpb.2019.11.005. Epub 2019 Nov 20.
7
Accessing neuroinflammation sites: Monocyte/neutrophil-mediated drug delivery for cerebral ischemia.神经炎症部位的药物递送:单核细胞/中性粒细胞介导的脑缺血药物递送。
Sci Adv. 2019 Jul 10;5(7):eaau8301. doi: 10.1126/sciadv.aau8301. eCollection 2019 Jul.
8
Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation.通过新型白蛋白包覆纳米晶体制剂拓展卡非佐米在乳腺癌治疗中的治疗用途。
J Control Release. 2019 May 28;302:148-159. doi: 10.1016/j.jconrel.2019.04.006. Epub 2019 Apr 4.
9
Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals.用白蛋白包被的纳米晶体增强多西他赛对多药耐药癌细胞的递送。
Mol Pharm. 2018 Jan 29. doi: 10.1021/acs.molpharmaceut.7b00783.
10
Albumin-coated nanocrystals for carrier-free delivery of paclitaxel.白蛋白包覆纳米晶体用于无载体递送紫杉醇。
J Control Release. 2017 Oct 10;263:90-101. doi: 10.1016/j.jconrel.2016.12.040. Epub 2016 Dec 31.
用于亚微观药物载体(如纳米颗粒和脂质体)特性分析的浊度光谱法:粒径测定。
Pharm Res. 2011 Sep;28(9):2204-22. doi: 10.1007/s11095-011-0448-z. Epub 2011 May 17.
4
Understanding improved dissolution of indomethacin through the use of cohesive poorly water-soluble aluminium hydroxide: effects of concentration and particle size distribution.通过使用具有粘性的难溶性氢氧化铝来理解吲哚美辛溶出度的提高:浓度和粒度分布的影响
J Pharm Sci. 2011 Oct;100(10):4269-80. doi: 10.1002/jps.22605. Epub 2011 May 10.
5
Intact nanoparticulate indomethacin in fast-dissolving carrier particles by combined wet milling and aerosol flow reactor methods.通过联合湿磨和气流式反应器方法制备完整的纳米载药粒子中的非那西丁。
Pharm Res. 2011 Oct;28(10):2403-11. doi: 10.1007/s11095-011-0456-z. Epub 2011 May 4.
6
Influence of particle size on the ultraviolet spectrum of particulate-containing solutions: implications for in-situ concentration monitoring using UV/Vis fiber-optic probes.粒径对含颗粒物溶液紫外光谱的影响:对使用紫外/可见光纤探头进行原位浓度监测的启示。
Pharm Res. 2011 Jul;28(7):1643-52. doi: 10.1007/s11095-011-0399-4. Epub 2011 Mar 4.
7
Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.盐酸瑞伐拉赞纳米混悬剂的制备及体外/体内评价。
Int J Pharm. 2011 Apr 15;408(1-2):157-62. doi: 10.1016/j.ijpharm.2011.01.059. Epub 2011 Feb 2.
8
State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery.纳米晶体的最新技术——特殊性质、生产、纳米毒理学方面和细胞内递呈。
Eur J Pharm Biopharm. 2011 May;78(1):1-9. doi: 10.1016/j.ejpb.2011.01.007. Epub 2011 Jan 23.
9
Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.含有微粉化或纳米化非诺贝特的产品的生物相关体外溶出度测试,旨在预测其血浆浓度曲线。
Eur J Pharm Biopharm. 2011 Feb;77(2):257-64. doi: 10.1016/j.ejpb.2010.10.012. Epub 2010 Nov 11.
10
Standardized in vitro drug release test for colloidal drug carriers using modified USP dissolution apparatus I.采用改良的美国药典溶出仪对胶体药物载体进行标准化体外药物释放试验 I。
Drug Dev Ind Pharm. 2011 Feb;37(2):178-84. doi: 10.3109/03639045.2010.502534. Epub 2010 Aug 12.